Permanent hypogonadism after traumatic brain injury: a case report
DOI:
https://doi.org/10.6092/1828-6550/APMB.106.1.2018.A7Palabras clave:
hypogonadism, traumatic brain injury, pituitaryResumen
We report here a case of male post-traumatic hypogonadism, whose clinical manifestations occurred three years after a traumatic brain injury (TBI). The selective pituitary deficit was proven to be irreversible by discontinuing for six months testosterone replacement. The present case confirms that gonadotrophs failure is not uncommon after a TBI. Therefore, regular pituitary function monitoring after a TBI, especially if associated with loss of consciousness, is important for the early detection of hypopituitarism.Referencias
1. Bhasin, S., Cunningham, G.R., Hayes, F.J., Matsumoto, A.M., Snyder, P.J., Swerdloff, R.S., Montori, V.M.; Task Force, Endocrine Society. (2010). Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab, 95(6), 2536-2559. doi: 10.1210/jc.2009-2354
2. Tanriverdi, F., Schneider, H.J., Aimaretti, G., Masel, B.E., Casanueva F.F., Kelestimur, F. (2015). Pituitary dysfunction after traumatic brain injury: a clinical and pathophysiological approach. Endocr Rev, 36(3), 305-342. doi: 10.1210/er.2014-1065
3. Benvenga, S., Bonardelli, M., Trimarchi, F., Degli Uberti, E.C. (2005) Ipopituitarismo e trauma cranico. L’Endocrinologo 6(3), 115-120.
4. Benvenga, S., Campenni, A., Ruggeri, R.M., Trimarchi, F. (2000). Clinical review 113: Hypopituitarism secondary to head trauma. J Clin Endocrinol Metab, 85(4), 1353–1361. doi: 10.1210/jcem.85.4.6506
5. Benvenga, S., Lo Giudice, F., Campenni, A., Longo, M., Trimarchi, F. (1997). Post-traumatic selective hypogonadotropic hypogonadism. J Endocrinol Invest, 20(11), 675-680. doi: 10.1007/BF03348031
6. Abraham, C., Cho, J.H. (2009). Inflammatory bowel disease. N Engl J Med, 361(21), 2066-2078. doi: 10.1056/NEJMra0804647
7. Tigas, S., Tsatsoulis, A. (2012). Endocrine and metabolic manifestations in inflammatory bowel disease. Ann Gastroenterol, 25(1), 37-44.
8. Abali, R., Tasdemir, N., Yuksel, M.A., Guzel, S., Oznur, M., Nalbantoglu, B., Tasdemir, U.G. (2013). Protective effect of infliximab on ischemia/reperfusion injury in a rat ovary model: biochemical and histopathologic evaluation. Eur J Obstet Gynecol Reprod Biol, 171(2), 353-357. doi:10.1016/j.ejogrb.2013.09.037
9. Said, T.M., Agarwal, A., Falcone, T., Sharma, R.K., Bedaiwy, M.A., Li, L. (2005). Infliximab may reverse the toxic effects induced by tumor necrosis factor alpha in human spermatozoa: an in vitro model. Fertil Steril 83(6), 1665-1673. doi: 10.1016/j.fertnstert.2004.11.068
DeBoer, M.D., Thayu, M., Griffin, L.M., Baldassano, R.N., Denson, L.A., Zemel, B.S., Denburg, M.R., Agard, H.E., Herskovitz, R., Long, J., Leonard, M.B. (2016). Anti-Tumor Necrosis Factor α Therapy in Adolescents with Crohn's Disease. J Pediatr 171, 146-152.e1-2. doi: 10.1016/j.jpeds.2016.01.003
Descargas
Publicado
Número
Sección
Licencia

This work is licensed under a Creative Commons Attribution 4.0 International License.
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).